Why One Drug Company Held Back a Better Drugnews2023-09-07T10:00:12+00:00September 7th, 2023|The New York Times|
How Gilead Profited by Slow-Walking a Promising H.I.V. Therapynews2023-07-22T18:26:55+00:00July 22nd, 2023|The New York Times|
Gilead Wins Key Patent Rights Suit Over HIV Prevention Drug PrEPnews2023-05-09T17:34:57+00:00May 9th, 2023|The New York Times|
F.D.A. Approves Remdesivir for Patients Not Hospitalizednews2022-01-22T16:58:04+00:00January 22nd, 2022|The New York Times|
